Lithium ascorbate shows early promise for depression and weight loss

New research points to lithium ascorbate as a potentially useful add-on for people with depressive symptoms and excess weight, with early data showing antidepressant-like effects, weight-loss gains and no reported adverse effects in a pilot program. The findings are preclinical and early-stage, but they suggest a possible alternative to lithium forms that can raise safety and weight-gain concerns.

Why it matters: - Depression and obesity often occur together, making treatment harder and increasing the need for options that can address mood and weight at the same time. - Lithium remains a possible add-on treatment for treatment-resistant depression, but standard forms raise concerns about toxicity, kidney and thyroid monitoring, and weight gain. - Lithium ascorbate could offer a lower-risk lithium option if the early findings hold up in larger studies.

What happened: - New research highlighted lithium ascorbate, an alternative lithium formulation, for antidepressant-like effects, favorable preclinical safety and promising weight-control results. - The pilot study took place in a structured weight-loss program at the Doctor Bormental center in Moscow, Russia. - Of 132 people screened, 69.7% showed signs of depression. - Participants with depressive symptoms were split into two groups, and both groups followed the same weight-loss program. - One group also received lithium ascorbate.

The details: - By month three, the lithium ascorbate group had lost an average of 26 pounds. - The control group lost an average of 19 pounds over the same period. - The researchers said the program was 38.4% more effective in the lithium ascorbate group by the end of the third month. - Participants reported a more stable emotional state, generally starting in weeks two to three and continuing while they took lithium ascorbate. - No adverse effects or complaints were reported during the study. - The research contrasted lithium ascorbate with other lithium salts, including lithium carbonate and lithium orotate. - Lithium carbonate requires regular blood monitoring and can affect kidney and thyroid function. - Preclinical studies have suggested lithium orotate may lead to 16% weight gain. - Lithium ascorbate has shown low toxicity and substantially less weight gain in preclinical studies. - Research cited in the release says people with obesity have a higher risk of developing depression, while people with major depression have a 71% greater risk of developing obesity. - People with obesity may also have a higher risk of treatment-resistant depression.

Between the lines: - The study is early and appears to be small, so it does not prove lithium ascorbate is safe or effective for broad use. - The most important signal is practical: a mood-supporting lithium form may help people stick with behavioral changes that drive weight loss. - If confirmed, lithium ascorbate could matter most for patients whose depression and weight gain reinforce each other.

What's next: - Larger, longer studies would be needed to test whether the weight-loss and mood benefits hold up. - Future research will also need to confirm whether lithium ascorbate avoids the safety and weight-gain issues tied to other lithium salts. - If results are replicated, lithium ascorbate could become a candidate add-on therapy for people with depressive symptoms and obesity.

The bottom line: - Lithium ascorbate is an early-stage candidate with a potentially useful combination of mood support, weight-loss help and a better safety profile than other lithium forms.